Clinical Trial Update: A Phase 3, Multicenter, Open-label Continuation Study in Moderate to Severe Asthmatic Subjects Who Completed FlutiForm HFA pMDI Study SKY2028-3-005 [Phase 3]

View source ↗

Summary

Phase 3 open-label continuation study in moderate-to-severe asthma patients who completed the SKY2028-3-005 trial of FlutiForm HFA inhalation therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• FlutiForm HFA

Snippet

Sponsor: SkyePharma AG | Conditions: Asthma | Phase 3 | Status: COMPLETED